5-aryl-1-imino-1-oxo-[1,2,4]thiadiazines

US9605006B2 · kind B2 · utility

Assignee

• Hoffmann-La Roche Inc. · US

Inventors

• Wolfgang Guba · Memmingen, DE
• Wolfgang Haap · Bad Kötzting, DE
• Andreas Kuglstatter · Soest, DE
• Jens-Uwe Peters · Weil am Rhein, DE
• Ulrike Obst Sander · Sursee, CH
• Christian Schnider · Basel, CH
• Roger Wermuth · Sissach, CH
• Thomas Woltering · Freiburg (Elbe), DE

Key dates

• Filing date: Dec 17, 2014
• Grant date: Mar 28, 2017
• Expiry date: Dec 17, 2034

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides a compound of formula I′ having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease.